SCHEMBL5142376

SCHEMBL5142376

O=C(Nc1cccc(Cl)c1)C(C(=O)Nc1cccc(Cl)c1)C(c1ccc(C(F)(F)F)cc1)N1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
RECQL P46063 1/20 0.46
LMNA P02545 2/20 0.46
RAB9A P51151 2/20 0.44
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 1/20 0.43
CCR3 P51677 2/20 0.42
P2RY1 P47900 1/20 0.42
HPGD P15428 1/20 0.41
RHOC P08134 1/20 0.41
RHOA P61586 1/20 0.41
MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5141402 0.76 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA
SCHEMBL5141401 0.73 RAB9A (0.50) SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL161516 0.70 BAZ1A (0.71) SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL17270209 0.69 ACKR3 (0.73) MEN1KMT2ALMNARAB9AMAPT
SCHEMBL1419999 0.68 NPC1 (0.57) ALDH1A1MEN1KMT2ANPSR1RECQL
SCHEMBL8368524 0.67 MAPT (0.58) SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL9795519 0.67 MAPT (0.58) SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL1754082 0.67 HDAC1 (0.64)
SCHEMBL12476809 0.66 MEN1 (0.97) SMN1; SMN2ALDH1A1MEN1KMT2ANPSR1
SCHEMBL14459434 0.66 KMT2A (0.74) SMN1; SMN2ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 SMN1; SMN2 1428/4885ALDH1A1 952/4885MEN1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.